Litcius/Paper detail

IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer

Heng Liang, Tianqi Li, Xin Fang, Zikang Xing, Shengnan Zhang, Lei Shi, Weirui Li, Leilei Guo, Chunxiang Kuang, Hongrui Liu, Qing Yang

2021Cancer Letters67 citationsDOI

Topics & Concepts

Pancreatic cancerCancer researchCancerDual (grammatical number)MedicinePharmacologyInternal medicineArtLiteratureTryptophan and brain disordersImmune cells in cancerEpigenetics and DNA Methylation
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer | Litcius